Washington, DC, United States of America

Allan L Goldstein

USPTO Granted Patents = 24 (Patent Applications = 10)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 2.1

ph-index = 9

Forward Citations = 228(Granted Patents)

Location History:

Galveston, TX (US) (1977 - 1978)
Bethesda, MD (US) (1996)
Bethedsa, MD (US) (1997)
Washington, DC (US) (1981 - 2018)

Company Filing History:

9 out of 12

Regenerx Biopharmaceuticals, Inc.

patents

7 out of 1,591

Washington University

patents

3 out of 4,948

Hoffmann-La Roche Inc.

patents

4. 3 out of 5

Viral Technologies, Inc.

patents

5. 2 out of 5,463

The University of Texas System

patents

6. 1 out of 3,540

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

7. 1 out of 28

The United States of America as Represented by the Secretary of Health

patents

8. 1 out of 504

Albert Einstein College of Medicine

patents

where one patent can have more than one assignee

Years Active: 1977-2018

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10004785 - LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized (2018-06-26),

2. 9821030 - LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized (2017-11-21),

3. 9585941 - Eye drop formulation (2017-03-07),

4. 9056087 - Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives (2015-06-16),

5. 8716215 - Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease (2014-05-06),

6. 8399609 - Treating or preventing extracellular matrix build-up (2013-03-19),

7. 8399412 - Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating NF-kappabeta or supressing NF-kappabeta-mediated actions (2013-03-19),

8. 8383576 - LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized (2013-02-26),

9. 8143218 - Treatment of skin, and wound repair, with thymosin beta 4 (2012-03-27),

10. 7268118 - Thymosin β4 compositions (2007-09-11),

11. 6197751 - Thymosin &agr;1 promotes tissue repair, angiogenesis and cell migration (2001-03-06),

12. 5702707 - Diagnostic method and test kit for the serological detection of the AIDS (1997-12-30),

13. 5665536 - Diagnastic method and test kit for the serological detection of the AIDS (1997-09-09),

14. 5593964 - Method of treating septic shock by preventing actin polymerization (1997-01-14),

15. 5585234 - Treatment of infertile sperm in vitro with thymosin .alpha..sub.1 to (1996-12-17),

Title: Innovator Spotlight: Allan L Goldstein - Pioneering Peptide Compositions

Introduction:

Allan L Goldstein is a distinguished inventor based in Washington, DC, with a remarkable portfolio of 24 patents to his name. His groundbreaking work in peptide compositions has garnered acclaim in the field of biopharmaceuticals and beyond.

Latest Patents:

Recently, Allan L Goldstein secured patents for his innovative LKKTET and LKKTNT peptide compositions. These compositions, whether lyophilized or in a form capable of being lyophilized, contain peptide agents with specific amino acid sequences. The inclusion of stabilizing agents ensures the integrity of the composition, making it a significant advancement in the industry.

Career Highlights:

Throughout his career, Allan L Goldstein has made significant contributions to the field of biopharmaceuticals. He has been associated with esteemed organizations such as Regenerx Biopharmaceuticals, Inc. and The George Washington University, where his expertise and innovative spirit have driven research and development efforts to new heights.

Collaborations:

An inventor of Allan L Goldstein's caliber does not work in isolation. He has collaborated with talented individuals in the field, including coworkers Teresa L Low and Gabriel Sosne. Together, they have combined their knowledge and skills to push the boundaries of scientific innovation.

Conclusion:

Allan L Goldstein's passion for invention and his dedication to advancing peptide compositions have solidified his reputation as a trailblazer in the industry. His patented creations stand as a testament to his ingenuity and commitment to shaping the future of biopharmaceuticals. We look forward to witnessing more groundbreaking developments from this visionary inventor.

This text is generated by artificial intelligence and may not be accurate.